A simple accurate method for concentration-QTc analysis in preclinical animal models

Area of Science:

• Cardiovascular Pharmacology
• Drug Safety Assessment

Background:

• Preclinical cardiovascular safety studies focus on rate-corrected QT interval (QTc) for predicting clinical changes.
• Limited pharmacokinetic (PK) data in nonclinical studies hinders concentration-QTc modeling.
• Averaging sparse PK data and QTc measurements can establish a concentration-QTc relationship.

Purpose of the Study:

• To develop and validate a method for establishing a concentration-QTc relationship using averaged preclinical data.
• To bridge statistical and concentration-QTc modeling approaches in cardiovascular safety pharmacology.
• To assess the feasibility of concentration-QTc analysis despite practical constraints in data collection.

Main Methods:

• Cardiovascular telemetry studies were performed in non-human primates (NHP) and canines.
• Average plasma concentrations (CAverage0-X) were calculated for specific time intervals.
• QTc effects were determined using linear regression, incorporating QT and heart rate (HR) data within super-intervals.
• Concentration-QTc effects were modeled using these averaged values.

Main Results:

• In NHP, a 10.9 ms QTc change was observed at 1.5x the human therapeutic moxifloxacin concentration.
• Simulated drugs with no QT effects showed no QTc changes up to 3x clinical concentrations.
• In canines, a 16.6 ms QTc change was detected at 1.7x critical clinical moxifloxacin concentration.

Conclusions:

• Averaging drug plasma concentrations and QTc data over time provides a viable method for concentration-QTc analysis.
• This super-interval approach effectively addresses cardiovascular safety questions when preclinical exposures exceed clinical levels.
• The method demonstrates a simple and effective way to bridge statistical and concentration-QTc modeling in drug development.